Business
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab AnalysisReducing inflammation helps create a regenerative environment in the Central Nervous System\nTORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data demonstrating that its proprietary exosomes can significantly reduce inflammatory activity compared to untreated cells and cells treated with a commercially available exosome product. “Inflammation and regeneration are conflicting biological processes, and this is particularly relevant in the Central Nervous System,” said Dr. Tali Kizhner, Director of Research & Development at NurExone. “These laboratory results show that our exosomes suppress inflammation more effectively than untreated cells and commercial alternatives, even at low concentrations, with stronger effects as the doses increase. This anti-inflammatory action is a part of our ExoPTEN approach, where exosomes and therapeutic cargo work synergistically to support regenerative pathways.” Building analytical depth and platform strength These findings build on NurExone’s December 12, 2025 news release, reporting analytical data demonstrating that its exosomes, produced from human bone marrow–derived mesenchymal stem cells (“MSC”), exhibit significantly higher biological activity compared with a commercially available MSC derived exosome as a control. “We are building an analytical framework to understand and quantify the true biological complexity of exosome-based therapeutics,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “This will help ensure consistency from batch to batch, support quality and regulatory readiness, and clearly explain the benefits of our exosomes relative to commercial alternatives. This is essential not only for advancing our own drug programs, such as ExoPTEN, but also for establishing a reliable, scalable platform for exosome-based drug delivery.” In the Company’s laboratory analysis, immune cells were stimulated to produce a strong inflammatory response, creating a controlled inflammatory environment. These untreated inflamed cells served as the controlled bas...